[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,052,834
  • Shares Outstanding, K 68,533
  • Annual Sales, $ 189,760 K
  • Annual Income, $ -196,540 K
  • EBIT $ -197 M
  • EBITDA $ -196 M
  • 60-Month Beta 1.94
  • Price/Sales 33.58
  • Price/Cash Flow N/A
  • Price/Book 51.84

Options Overview Details

View History
  • Implied Volatility 82.27% (unch)
  • Historical Volatility 49.78%
  • IV Percentile 86%
  • IV Rank 59.10%
  • IV High 112.19% on 07/08/25
  • IV Low 39.01% on 08/11/25
  • Expected Move (DTE 19) 15.93 (18.04%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 13
  • Volume Avg (30-Day) 162
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 3,156
  • Open Int (30-Day) 3,027
  • Expected Range 72.39 to 104.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.84
  • Number of Estimates 6
  • High Estimate $-0.78
  • Low Estimate $-0.94
  • Prior Year $-0.75
  • Growth Rate Est. (year over year) -12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.40 +11.23%
on 05/01/26
99.00 -10.79%
on 05/05/26
+6.20 (+7.55%)
since 04/29/26
3-Month
74.50 +18.55%
on 03/30/26
100.00 -11.68%
on 03/20/26
-4.41 (-4.76%)
since 02/27/26
52-Week
60.06 +47.05%
on 05/29/25
122.20 -27.73%
on 12/11/25
+28.73 (+48.21%)
since 05/28/25

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 88.32 (-5.01%)
3 Gold-Medal Mutual Funds to Buy Now

These mutual funds are the crème de la crème of their respective investment categories.

NVDA : 211.14 (-1.45%)
GOOGL : 380.34 (-2.51%)
ONC : 287.92 (-0.92%)
TDVG : 48.01 (+0.08%)
RYTM : 88.32 (-5.01%)
MU : 971.00 (+5.14%)
DODIX : 12.77 (+0.08%)
V : 326.36 (+0.43%)
ROST : 231.73 (+1.99%)
PRDGX : 87.12 (+0.16%)
CB : 311.73 (-1.42%)
WMT : 115.75 (-2.65%)
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 88.32 (-5.01%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 88.32 (-5.01%)
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France – – Phase 3 analyses...

RYTM : 88.32 (-5.01%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 88.32 (-5.01%)
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026...

RYTM : 88.32 (-5.01%)
Will Rhythm Pharmaceuticals Finally Explain How It Plans to Keep Growing Beyond the Obvious?

Barchart Research What to Expect from RYTM Earnings RYTM Generated May 4, 2026 Current Price $85.58 EPS Estimate $$-0.86 Consensus Rating Strong Buy Average Move 4.34% Will Rhythm Pharmaceuticals Finally...

RYTM : 88.32 (-5.01%)
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pediatric...

RYTM : 88.32 (-5.01%)
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired...

RYTM : 88.32 (-5.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 97.41
2nd Resistance Point 95.45
1st Resistance Point 91.89
Last Price 88.32
1st Support Level 86.37
2nd Support Level 84.41
3rd Support Level 80.85

See More

52-Week High 122.20
Fibonacci 61.8% 98.46
Fibonacci 50% 91.13
Last Price 88.32
Fibonacci 38.2% 83.80
52-Week Low 60.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.